Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.

Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.

Sorafenib, a multikinase inhibitor of cell proliferation and angiogenesis, inhibits the mitogen-activated protein kinase pathway that is activated in most uveal melanoma tumors. This phase II study was conducted by the SWOG cooperative group to evaluate the efficacy of sorafenib in combination with...

Full description

Bibliographic Details
Main Authors: Shailender Bhatia, James Moon, Kim A Margolin, Jeffrey S Weber, Christopher D Lao, Megan Othus, Ana M Aparicio, Antoni Ribas, Vernon K Sondak
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3511501?pdf=render

Internet

http://europepmc.org/articles/PMC3511501?pdf=render

Similar Items